[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
December 6, 2000

Preventive Use for Ramipril

Author Affiliations

Not Available

Not Available

JAMA. 2000;284(21):2711. doi:10.1001/jama.284.21.2711-JFD00010-3-1

The FDA has approved labeling for a new use for the antihypertensive drug ramipril (Altace, Aventis Pharmaceuticals, Kansas City, Mo), an ACE inhibitor, to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes.

The new indication is limited to patients 55 years or older who are at high risk for developing a major cardiovascular event because of history of coronary artery disease, stroke, peripheral vascular disease, or type 1 or 2 diabetes that is accompanied by at least one other cardiovascular risk factor, such as hypertension, cigarette smoking, elevated total cholesterol levels, low HDL level, or proteinuria. Ramipril can be used in addition to other treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview